<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684368</url>
  </required_header>
  <id_info>
    <org_study_id>ACNS2021</org_study_id>
    <secondary_id>NCI-2020-13175</secondary_id>
    <secondary_id>ACNS2021</secondary_id>
    <secondary_id>ACNS2021</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT04684368</nct_id>
  </id_info>
  <brief_title>A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT</brief_title>
  <official_title>A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &amp;Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the best approach to combine chemotherapy and radiation therapy&#xD;
      (RT) based on the patient's response to induction chemotherapy in patients with&#xD;
      non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain&#xD;
      or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond&#xD;
      well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose&#xD;
      chemotherapy followed by conventional RT in patients who did not respond to induction&#xD;
      chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells, by&#xD;
      stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high&#xD;
      energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have&#xD;
      shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to&#xD;
      chemotherapy before receiving radiation therapy, are more likely to be free of the disease&#xD;
      for a longer time than are patients for whom the chemotherapy does not efficiently eliminate&#xD;
      or reduce the size of the tumor. The purpose of this study is to see how well the tumors&#xD;
      respond to induction chemotherapy to decide what treatment to give next. Some patients will&#xD;
      be given RT to the spine and a portion of the brain. Others will be given high dose&#xD;
      chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving&#xD;
      treatment based on the response to induction chemotherapy may lower the side effects of&#xD;
      radiation in some patients and adjust the therapy to a more efficient one for other patients&#xD;
      with localized NGGCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To monitor outcome to ensure that children and young adults with localized central nervous&#xD;
      system (CNS) non-germinomatous germ cell tumors (NGGCT) treated with induction chemotherapy&#xD;
      followed by response evaluation and whole ventricular + spinal canal irradiation (WVSCI) will&#xD;
      maintain the excellent 2-year progression free survival (PFS) rate as compared to ACNS0122&#xD;
      (NCT00047320).&#xD;
&#xD;
      II. To improve disease control by decreasing the number of spinal relapses for patients who&#xD;
      achieve a complete response (CR) or partial response (PR) and receive WVSCI as compared to&#xD;
      whole ventricular radiation on ACNS1123 (NCT01602666).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the response rates to induction chemotherapy and WVSCI for localized NGGCT&#xD;
      patients who achieve a CR/PR.&#xD;
&#xD;
      II. To estimate the PFS and overall survival (OS) for localized NGGCT patients who achieve a&#xD;
      CR/PR and receive WVSCI.&#xD;
&#xD;
      III. To estimate the PFS and OS for patients with less than a CR/PR following Induction who&#xD;
      subsequently receive high-dose chemotherapy with peripheral stem cell rescue (HDCSCR).&#xD;
&#xD;
      IV. To estimate the response rate for patients with less than a CR/PR following Induction who&#xD;
      subsequently receive HDCSCR.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To prospectively compare outcomes based on radiation modality, photon versus proton,&#xD;
      including cognitive, social and behavioral functioning, auditory, and neuro-endocrine&#xD;
      function.&#xD;
&#xD;
      II. To compare spinal column growth and cell counts following radiation as measured by height&#xD;
      and weight, and complete blood count (CBC) values during and after radiation therapy, based&#xD;
      on treatment modality (photon versus [vs.] proton therapy) and planned inclusion/exclusion of&#xD;
      the vertebral body in patients &lt; 13 years of age.&#xD;
&#xD;
      III. To compare local vs. central review recommendations for second-look surgery and document&#xD;
      barriers for performing such surgeries as well as their clinical benefit in pediatric NGGCT.&#xD;
&#xD;
      IV. To prospectively evaluate and longitudinally model the cognitive, social, and behavioral&#xD;
      functioning of children and young adults with localized CNS NGGCT with testing as per the&#xD;
      Children's Oncology Group (COG) Standardized Neuropsychological and Behavioral Battery.&#xD;
&#xD;
      V. To evaluate patterns of disease recurrence/failure with respect to radiation dose&#xD;
      distribution.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION CHEMOTHERAPY: Patients receive carboplatin intravenously (IV) over 15-60 minutes on&#xD;
      day 1 and etoposide IV over 90-120 minutes on days 1-3 of cycles 1, 3, and 5. Patients also&#xD;
      receive ifosfamide IV over 60 minutes and etoposide IV over 60-120 minutes on days 1-5 of&#xD;
      cycles 2, 4, and 6. Treatment repeats every 21 days for up to 6 cycles in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are assigned to 1 of 2 plans (ventricular + spinal canal irradiation [WVSCI] or&#xD;
      high-dose chemotherapy with peripheral stem cell rescue [HDCSCR]) based on response to&#xD;
      induction chemotherapy:&#xD;
&#xD;
        -  Patients who achieve radiographic CR/PR with marker normalization proceed to WVSCI.&#xD;
           Patients who achieve radiographic CR without marker normalization proceed to HDCSCR.&#xD;
&#xD;
        -  Patients who achieve less than radiographic CR/PR with marker normalization proceed to&#xD;
           second-look surgery (unless contraindicated). If second-look surgery reveals mature&#xD;
           teratoma or non-viable tumor, proceed to WVSCI. If second-look surgery reveals viable&#xD;
           tumor, proceed to HDCSCR. Patients who are unable to undergo second-look surgery are&#xD;
           removed from protocol therapy but remain on study for follow-up.&#xD;
&#xD;
        -  Patients who achieve less than radiographic CR/PR without marker normalization proceed&#xD;
           to second-look surgery (unless contraindicated). Patients then proceed to HDCSCR&#xD;
           regardless of whether or not a second-look surgery is performed.&#xD;
&#xD;
        -  Patients who achieve radiographic PR without marker normalization proceed to second-look&#xD;
           surgery (unless contraindicated). Patients then proceed to HDCSCR regardless of whether&#xD;
           or not a second-look surgery is performed.&#xD;
&#xD;
      PLAN A (WVSCI THERAPY): Within 6 weeks of the end of induction chemotherapy or second-look&#xD;
      surgery, patients undergo WVSCI once daily (QD) for 5 days weekly (17 fractions followed by a&#xD;
      boost dose for 13 fractions) for 6 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PLAN B (CONSOLIDATION THERAPY [HDCSCR]): Within 6-8 weeks of the end of induction&#xD;
      chemotherapy or second-look surgery, patients receive etoposide IV and thiotepa IV over 3&#xD;
      hours on days -5 to -3 and undergo peripheral blood stem cell (PBSC) transplant on day 0.&#xD;
      Patients then undergo radiation therapy QD for 5 days weekly (20 fractions followed by a&#xD;
      boost dose for 10 fractions) for 6 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">December 21, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2029</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure rate</measure>
    <time_frame>Within 2 years of enrollment</time_frame>
    <description>Will be measured by the number of progressions or deaths within 2 years of enrollment for the cohort treated with whole ventricular + spinal canal irradiation (WVSCI). The final analysis will include an exact binomial confidence interval of the failure rate for each of the failure types (local, distant/spinal or both) without adjustment for multiplicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spinal failure rate</measure>
    <time_frame>Within 2 years of enrollment</time_frame>
    <description>Will be measured by the number of spinal relapses (spine alone or distant relapses including the spine) within 2 years of enrollment in patients treated with WVSCI. The final analysis will include an exact binomial confidence interval of spinal failure rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic complete response (CR)/partial response (PR) with marker normalization rate post induction/second-look surgery</measure>
    <time_frame>Up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed in patients treated with induction chemotherapy. Will be estimated using an exact binomial approach and its confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic complete response (CR)/partial response (PR) with marker normalization rate post high-dose chemotherapy with peripheral stem cell rescue (HDCSCR)</measure>
    <time_frame>Up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed in patients treated with HDCSCR. Will be estimated using an exact binomial approach and its confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From enrollment until disease progression or death from any cause for patients with events, and until final follow up for those who are event free at the time of analysis, assessed up to 10 years</time_frame>
    <description>Will be estimated separately for those treated with WVSCI and with HDCSCR + radiation therapy. Kaplan-Maier based PFS curve estimates will be included, where patients who are lost to follow up will be treated as censored observations as part of the primary analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From enrollment until death from any cause for patients with events and until final follow up for those who are alive at the time of analysis, assessed up to 10 years</time_frame>
    <description>Will be estimated separately for those treated with WVSCI and with HDCSCR + radiation therapy. Kaplan-Maier based OS curve estimates will be included, where patients who are lost to follow up will be treated as censored observations as part of the secondary analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of disease recurrence/failure</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Will be analyzed in an exploratory manner with respect to radiation dose distribution.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in intelligence scores within each treatment arm</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the Wechsler Preschool and Primary Scale of Intelligence 4th Edition (WPPSI-IV), Wechsler Intelligence Scale for Children 5th Edition (WISC-V), and the Wechsler Adult Intelligence Scale 4th Edition (WAIS-IV), depending on patient's age. One-sample confidence intervals will be used to estimate mean pairwise changes in intelligence scores between 2 time points within each treatment arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in intelligence scores between treatment arms</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the Wechsler Preschool and Primary Scale of Intelligence 4th Edition (WPPSI- IV), Wechsler Intelligence Scale for Children 5th Edition (WISC V), and the Wechsler Adult Intelligence Scale 4th Edition (WAIS-IV), depending on patient's age. A 2-sample confidence interval approach will be used to estimate the difference in score changes between the two cohorts (WVSCI versus HDCSCR) in order to describe differential effects of the 2 treatment strategies.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in processing speed/attention within each treatment arm</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the WISC-V or WAIS-IV processing speed index tasks. One-sample confidence intervals will be used to estimate mean pairwise changes in scores between 2 time points within each treatment arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in processing speed/attention between the two treatment arms</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the WISC-V or WAIS-IV processing speed index tasks. A 2-sample confidence interval approach will be used to estimate the difference in score changes between the two cohorts (WVSCI versus HDCSCR) in order to describe differential effects of the 2 treatment strategies.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in immediate visual memory within each arm</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the Children's Memory Scale and California Verbal Learning Test. One-sample confidence intervals will be used to estimate mean pairwise changes in scores between 2 time points within treatment arms, as appropriate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in social-emotional functioning within each arm</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the Behavior Assessment System for Children - 3rd Edition. One-sample confidence intervals will be used to estimate mean pairwise changes in scores between 2 time points within treatment arms, as appropriate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in adaptive functioning within each arm</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the Adaptive Behavior Assessment System - 3rd Edition. One-sample confidence intervals will be used to estimate mean pairwise changes in scores between 2 time points within treatment arms, as appropriate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in health-related quality of life within each arm</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the Pediatric Quality of Life Inventory version 4.0. One-sample confidence intervals will be used to estimate mean pairwise changes in scores between 2 time points within treatment arms, as appropriate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in health-related quality of life between the two treatment arms</measure>
    <time_frame>Baseline up to 60 months post-treatment initiation</time_frame>
    <description>Will be assessed by the Pediatric Quality of Life Inventory version 4.0. 2-sample confidence interval approach will be used to estimate the difference in score changes between the two cohorts (WVSCI versus HDCSCR) in order to describe differential effects of the 2 treatment strategies.</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiation modality (proton versus photon)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Will summarize and compare functional outcomes, including cognitive, social and behavioral functioning, and auditory and neuro-endocrine function, in the context of the radiation therapy modality used. Two sample t-tests for specified timepoints within each of the two treatment cohorts (WVSCI versus HDCSCR) will be used for comparisons.</description>
  </other_outcome>
  <other_outcome>
    <measure>Growth comparisons following radiation by radiation modality</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Will compare early and late outcomes for proton and photon therapy with and without vertebral body sparing. Height and weight of subjects who are &lt; 13 years at the time of radiation therapy will be collected until subjects go off study or reach the age of 21, whichever is earlier. Percentile values standardizing height and weight based on appropriate growth curves will be used to compare cohorts treated with proton- versus photon-based radiation therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Complete blood count values following radiation by radiation modality</measure>
    <time_frame>Up to 1 year post treatment initiation</time_frame>
    <description>Complete blood count values during radiation therapy will be used to compare these outcomes in the context of proton- versus photon-based radiation therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Local versus central review recommendations for second-look surgery</measure>
    <time_frame>Up to 1 year post treatment initiation</time_frame>
    <description>Will summarize the local versus central review recommendations for second-look surgery and document any discrepancies.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Central Nervous System Nongerminomatous Germ Cell Tumor</condition>
  <condition>Choriocarcinoma</condition>
  <condition>Embryonal Carcinoma</condition>
  <condition>Immature Teratoma</condition>
  <condition>Malignant Teratoma</condition>
  <condition>Mixed Germ Cell Tumor</condition>
  <condition>Pineal Region Germ Cell Tumor</condition>
  <condition>Pineal Region Immature Teratoma</condition>
  <condition>Pineal Region Yolk Sac Tumor</condition>
  <condition>Suprasellar Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Outline in Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Outline in Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given subcutaneously (SC) or IV</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>Filgrastim-aafi</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>Nivestym</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>Asta Z 4942</other_name>
    <other_name>Asta Z-4942</other_name>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Holoxane</other_name>
    <other_name>Ifex</other_name>
    <other_name>IFO</other_name>
    <other_name>IFO-Cell</other_name>
    <other_name>Ifolem</other_name>
    <other_name>Ifomida</other_name>
    <other_name>Ifomide</other_name>
    <other_name>Ifosfamidum</other_name>
    <other_name>Ifoxan</other_name>
    <other_name>IFX</other_name>
    <other_name>Iphosphamid</other_name>
    <other_name>Iphosphamide</other_name>
    <other_name>Iso-Endoxan</other_name>
    <other_name>Isoendoxan</other_name>
    <other_name>Isophosphamide</other_name>
    <other_name>Mitoxana</other_name>
    <other_name>MJF 9325</other_name>
    <other_name>MJF-9325</other_name>
    <other_name>Naxamide</other_name>
    <other_name>Seromida</other_name>
    <other_name>Tronoxal</other_name>
    <other_name>Z 4942</other_name>
    <other_name>Z-4942</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>2-Mercaptoethanesulfonate, Sodium Salt</other_name>
    <other_name>Ausobronc</other_name>
    <other_name>D-7093</other_name>
    <other_name>Filesna</other_name>
    <other_name>Mercaptoethane Sulfonate</other_name>
    <other_name>Mercaptoethanesulfonate</other_name>
    <other_name>Mesnex</other_name>
    <other_name>Mesnil</other_name>
    <other_name>Mesnum</other_name>
    <other_name>Mexan</other_name>
    <other_name>Mistabron</other_name>
    <other_name>Mistabronco</other_name>
    <other_name>Mitexan</other_name>
    <other_name>Mucofluid</other_name>
    <other_name>Mucolene</other_name>
    <other_name>UCB 3983</other_name>
    <other_name>Uromitexan</other_name>
    <other_name>Ziken</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>filgrastim-SD/01</other_name>
    <other_name>Fulphila</other_name>
    <other_name>HSP-130</other_name>
    <other_name>Jinyouli</other_name>
    <other_name>Neulasta</other_name>
    <other_name>Neulastim</other_name>
    <other_name>Nyvepria</other_name>
    <other_name>Pegcyte</other_name>
    <other_name>Pegfilgrastim Biosimilar HSP-130</other_name>
    <other_name>Pegfilgrastim Biosimilar Nyvepria</other_name>
    <other_name>Pegfilgrastim Biosimilar Pegcyte</other_name>
    <other_name>Pegfilgrastim Biosimilar Udenyca</other_name>
    <other_name>Pegfilgrastim Biosimilar Ziextenzo</other_name>
    <other_name>pegfilgrastim-apgf</other_name>
    <other_name>pegfilgrastim-bmez</other_name>
    <other_name>pegfilgrastim-cbqv</other_name>
    <other_name>Pegfilgrastim-jmdb</other_name>
    <other_name>SD-01</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
    <other_name>Udenyca</other_name>
    <other_name>Ziextenzo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo PBSC transplant</description>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo WVSCI radiation therapy</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>ENERGY_TYPE</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy, NOS</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>ENERGY_TYPE</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy, NOS</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Second-Look Surgery</intervention_name>
    <description>Undergo second-look surgery if needed</description>
    <arm_group_label>Plan A (chemotherapy, WVSCI, second-look surgery if needed)</arm_group_label>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>Reoperation</other_name>
    <other_name>Repeat Surgery</other_name>
    <other_name>Second Look</other_name>
    <other_name>Surgical Revision</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Plan B (chemotherapy, HDCSCR, second-look surgery if needed)</arm_group_label>
    <other_name>1,1'',1''''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N'', N''''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be &gt;= 3 years and &lt; 30 years at the time of study enrollment&#xD;
&#xD;
          -  Patients must be newly diagnosed with localized primary CNS NGGCT of the suprasellar&#xD;
             and/or pineal region by pathology and/or serum or cerebrospinal fluid (CSF) elevation&#xD;
             of AFP above institutional normal or &gt; 10 ng/mL or human chorionic gonadotropin (hCG)&#xD;
             beta &gt; 100 mIU/mL. Suprasellar, pineal and bifocal tumors are included. (CSF tumor&#xD;
             markers and cytology must be within 21 days prior to enrollment and within 35 days&#xD;
             prior to start of protocol therapy [repeat if necessary]. Serum tumor markers, AFP and&#xD;
             hCGbeta must be within 7 days prior to enrollment and start of protocol therapy&#xD;
             [repeat if necessary]). Basal ganglia or other primary sites are excluded&#xD;
&#xD;
          -  Patients with any of the following pathological elements are eligible: endodermal&#xD;
             sinus (yolk sac), embryonal carcinoma, choriocarcinoma, malignant/immature teratoma&#xD;
             and mixed germ cell tumor (GCT) (i.e., may include some pure germinoma) if malignant&#xD;
             elements listed above are present. Patients with only mature teratoma are excluded.&#xD;
             Patients with pure germinoma admixed with mature teratoma are excluded (would be&#xD;
             eligible for pure germinoma protocols)&#xD;
&#xD;
          -  Patients must have a cranial magnetic resonance imaging (MRI) with and without&#xD;
             gadolinium at diagnosis/prior to enrollment. If surgical resection is performed,&#xD;
             patients must have pre-operative and post operative brain MRI with and without&#xD;
             gadolinium. The post operative brain MRI should be obtained within 72 hours of&#xD;
             surgery. If patient has a biopsy only, post-operative brain MRI is recommended but not&#xD;
             required (within 14 days prior to study enrollment)&#xD;
&#xD;
          -  Patients must have a spine MRI with gadolinium obtained at diagnosis/prior to&#xD;
             enrollment. Spine MRI with and without gadolinium is recommended (within 14 days prior&#xD;
             to study enrollment)&#xD;
&#xD;
          -  Lumbar CSF must be obtained prior to study enrollment unless medically&#xD;
             contraindicated. If a patient undergoes surgery and lumbar CSF cytology cannot be&#xD;
             obtained at the time of surgery, then it should be performed at least 10 days&#xD;
             following surgery and prior to study enrollment. False positive cytology can occur&#xD;
             within 10 days of surgery&#xD;
&#xD;
          -  Patients must have CSF tumor markers obtained prior to enrollment unless medically&#xD;
             contraindicated. Ventricular CSF obtained at the time of CSF diversion procedure (if&#xD;
             performed) is acceptable for tumor markers but lumbar CSF is preferred. In case CSF&#xD;
             diversion and biopsy/surgery are combined, CSF tumor markers should be collected first&#xD;
&#xD;
          -  Peripheral absolute neutrophil count (ANC) &gt;= 1000/uL (within 7 days prior to&#xD;
             enrollment)&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/uL (transfusion independent) (within 7 days prior to&#xD;
             enrollment)&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days&#xD;
             prior to enrollment)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70&#xD;
             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows (within 7 days&#xD;
             prior to enrollment):&#xD;
&#xD;
               -  Age: Maximum serum creatinine (mg/dL)&#xD;
&#xD;
                    -  3 to &lt; 6 years: 0.8 (male), 0.8 (female)&#xD;
&#xD;
                    -  6 to &lt; 10 years: 1 (male), 1 (female)&#xD;
&#xD;
                    -  10 to &lt; 13 years: 1.2 (male), 1.2 (female)&#xD;
&#xD;
                    -  13 to &lt; 16 years: 1.5 (male), 1.4 (female)&#xD;
&#xD;
                    -  &gt;= 16 years: male (1.7), 1.4 (female)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) for age (within 7 days prior to&#xD;
             enrollment)&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 135&#xD;
             U/L (within 7 days prior to enrollment)&#xD;
&#xD;
               -  Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the&#xD;
                  value of 45 U/L&#xD;
&#xD;
          -  Central nervous system function defined as:&#xD;
&#xD;
               -  Patients with seizure disorder may be enrolled if on anticonvulsants and well&#xD;
                  controlled&#xD;
&#xD;
               -  Patients must not be in status epilepticus, coma or assisted ventilation prior to&#xD;
                  study enrollment&#xD;
&#xD;
          -  Protocol therapy must begin within 31 calendar days of definitive surgery or clinical&#xD;
             diagnosis. If a biopsy only was performed, the biopsy date will be considered the date&#xD;
             of definitive surgery. For patients who have a biopsy or incomplete resection at&#xD;
             diagnosis followed by additional surgery, the date of the last resection will be&#xD;
             considered the date of definitive surgery.&#xD;
&#xD;
          -  All patients and/or their parents or legal guardians must sign a written informed&#xD;
             consent&#xD;
&#xD;
          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute&#xD;
             (NCI) requirements for human studies must be met&#xD;
&#xD;
          -  NEUROCOGNITIVE FUNCTION AND QUALITY OF LIFE ASSESSMENT:&#xD;
&#xD;
          -  English-, Spanish-, or French- speaking&#xD;
&#xD;
               -  Note: Patients who speak a language other than English, Spanish, or French will&#xD;
                  be allowed to participate in ACNS2021 but will not complete the neurocognitive&#xD;
                  and quality of life assessments&#xD;
&#xD;
          -  No known history of neurodevelopmental disorder prior to diagnosis of NGGCT (e.g.,&#xD;
             Down syndrome, fragile X, William syndrome, intellectual disability). Patients with&#xD;
             NF1 will be allowed to participate&#xD;
&#xD;
          -  Additional eligibility criteria for the COG Standardized Neuropsychological Battery&#xD;
             only: must be at a site that has a psychologist to administer the battery&#xD;
&#xD;
               -  Note: If not eligible for the COG Standardized Battery, patients should still&#xD;
                  complete the Behavior Rating Inventory of Executive Function, Second Edition&#xD;
                  (BRIEF-2), Pediatric Quality of Life Inventory (PedsQL), Adaptive Behavior&#xD;
                  Assessment System Third Edition (ABAS-3), and Behavior Assessment System for&#xD;
                  Children, Third Edition (BASC-3) questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with tumors located outside the ventricles (i.e., basal ganglia, thalamus)&#xD;
&#xD;
          -  Patients with only mature teratoma and non-elevated markers upon tumor sampling at&#xD;
             diagnosis&#xD;
&#xD;
          -  Patients who have received any prior tumor-directed therapy for their diagnosis of&#xD;
             NGGCT other than surgical intervention and corticosteroids&#xD;
&#xD;
          -  Patients with metastatic disease (i.e., MRI evaluation, lumbar CSF cytology or&#xD;
             intraoperative evidence of dissemination)&#xD;
&#xD;
          -  Female patients who are pregnant, since fetal toxicities and teratogenic effects have&#xD;
             been noted for several of the study drugs&#xD;
&#xD;
               -  Note: Serum and urine pregnancy tests may be falsely positive due to&#xD;
                  HCGbeta-secreting germ cell tumors. Ensure the patient is not pregnant by&#xD;
                  institutional standards&#xD;
&#xD;
          -  Lactating females who plan to breastfeed their infants&#xD;
&#xD;
          -  Sexually active patients of reproductive potential who have not agreed to use an&#xD;
             effective contraceptive method for the duration of their study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon M MacDonald</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valley Children's Hospital</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>559-353-3000</phone>
      <email>Research@valleychildrens.org</email>
    </contact>
    <investigator>
      <last_name>Karen S. Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Laura A. Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>904-697-3529</phone>
    </contact>
    <investigator>
      <last_name>Scott M. Bradfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital/Children's Hospital-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>813-357-0849</phone>
      <email>jennifer.manns@baycare.org</email>
    </contact>
    <investigator>
      <last_name>Don E. Eslin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-226-4343</phone>
    </contact>
    <investigator>
      <last_name>Jaime M. Libes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-237-1225</phone>
    </contact>
    <investigator>
      <last_name>David S. Dickens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>601-815-6700</phone>
    </contact>
    <investigator>
      <last_name>Anderson (Andy) B. Collier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamed S. Abdelbaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists - Reno</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-235-8675</phone>
    </contact>
    <investigator>
      <last_name>Razia B. Akhtar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Stephen W. Gilheeney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>315-464-5476</phone>
    </contact>
    <investigator>
      <last_name>Philip M. Monteleone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Flower Hospital</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jamie L. Dargart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jamie L. Dargart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>503-413-2560</phone>
    </contact>
    <investigator>
      <last_name>Janice F. Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>412-692-8570</phone>
      <email>jean.tersak@chp.edu</email>
    </contact>
    <investigator>
      <last_name>James T. Felker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Aniket Saha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Aniket Saha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-226-4343</phone>
      <email>referralinfo@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Aditi Bagchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Timothy C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Teratoma</mesh_term>
    <mesh_term>Carcinoma, Embryonal</mesh_term>
    <mesh_term>Endodermal Sinus Tumor</mesh_term>
    <mesh_term>Choriocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

